Time to spin-in
Far more than their U.S. cousins, German biotech companies have been buffeted by the changing whims of investors regarding which business model to pursue. Today, it is once again fashionable - and fundable - to develop products, as exemplified by last week's decision by Evotec OAI AG to re-integrate its Evotec Neurosciences GmbH subsidiary.
Evotec (FSE:EVT, Hamburg, Germany) began life in 1993 as an evolutionary screening company focused on discovery in anti-infectives, and by 2000 was looking to become the pharmaceutical industry's partner of choice for high throughput screening and medicinal